20 Feb 2014, BioSpectrum Bureau , BioSpectrum
Singapore: TriReme Medical, a subsidiary of Singapore-based QT Vascular, has signed a broad distribution agreement with Cordis for the exclusive distribution of its unique Chocolate PTA Balloon Angioplasty Catheter, with an option for additional TriReme portfolio products. This agreement will expand TriReme's commercial footprint and allow the company to focus on its promising development pipeline.
"Cordis has an unparalleled track record in creating and building new and innovative product categories that have dramatically changed and improved clinical practice. We are honored to partner with Cordis and look forward to our collaboration," said Dr Eitan Konstantino, president and CEO, TriReme.
The Chocolate PTA Balloon Catheter, approved in the US in December 2011, is a PTA balloon that is designed to allow for atraumatic dilatation in treating peripheral artery disease (PAD). The Chocolate PTA Balloon Catheter is indicated for balloon dilatation of lesions in the peripheral vasculature, including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal and renal arteries. Not for use in the coronary or cerebral vasculature.
Its unique nitinol constraining structure creates uniform "pillows" that make contact with the vessel and 'valleys' that allow for plaque modification and are designed to relieve stress upon inflation.
"We are delighted to see TriReme gain this level of global recognition," stated Mr Michael Kleine, board member of QT Vascular and former CEO of Biosensors International. "TriReme management has been building a valuable business by driving strong market adoption for its products backed with excellent clinical data."